# A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

Source: https://onco.cc/trials/nct07265674/  
OnCo record `nct07265674` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nanvuranlat in biliary tract cancer, run by J-Pharma Co., Ltd., now recruiting.

## Summary

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer is a phase 3 interventional study registered as NCT07265674 by J-Pharma Co., Ltd., with 480 participants planned, started 2026-05-11 and due to reach its primary completion in 2027-10. Interventions recorded: Nanvuranlat.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07265674
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer
- Sponsor: J-Pharma Co., Ltd.
- Enrolled: 480

## Sources

- ClinicalTrials.gov NCT07265674: https://clinicaltrials.gov/study/NCT07265674

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07265674.json